LOTTE Biologics Songdo Plant 1 Lands First Major Commercial Manufacturing Agreement Ahead of Launch

Lotte Biologics News

LOTTE Biologics Songdo Plant 1 has secured its first major commercial manufacturing agreement with a global pharmaceutical company ahead of its operational launch. The deal covers integrated drug substance and drug product manufacturing, with commercial production targeted for 2027.

Pfizer Starna Licensing Agreement: Pfizer Secures Exclusive In Vivo CAR-T Rights for Autoimmune Diseases in $330 Million Upfront Deal

pfizer news

The Pfizer Starna licensing agreement hands Pfizer exclusive rights outside Greater China to three pre-IND in vivo CAR-T autoimmune programs, backed by a $330 million upfront payment and up to $2.3 billion in milestones.

Johnson & Johnson Announces $2.2 Billion Ollin Biosciences Acquisition to Add Phase 3 Eye Antibody OLN324

Johnson & Johnson Company Information

Johnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront, adding the Phase 3 bispecific antibody OLN324 for wet AMD and diabetic macular edema. A separate $750 million Blackstone Life Sciences funding agreement would support Phase 3 development.

FDA Rejected Ivonescimab: Summit Therapeutics Receives Complete Response Letter for NSCLC BLA Based on HARMONi Study

US FDA News

The FDA rejected ivonescimab in its present form, issuing a Complete Response Letter for Summit Therapeutics’ NSCLC BLA. The agency said a PFS benefit without significant overall survival does not establish substantial evidence of effectiveness.

Novo Nordisk CagriSema REDEFINE 9 Trial Shows ~21% Average Weight Loss at Lower Doses at ObesityWeek 2026

Novo Nordisk new logo Novo

Novo Nordisk’s phase 3 CagriSema REDEFINE 9 trial showed estimated average weight loss of 20.7% and 21.0% at 68 weeks with lower CagriSema doses, versus 2.0% with placebo. Results were presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology.

Novartis Rhapsido CIndU Data: Remibrutinib Shows Sustained Efficacy Through Week 52 in Phase III RemIND Study

novartis

Novartis reported 52-week Phase III RemIND results for Rhapsido (remibrutinib) in chronic inducible urticaria. Response rates held through Week 52 across symptomatic dermographism, cold urticaria and cholinergic urticaria, and additional regulatory submissions are planned.